Janet A. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Janet A. Thomas has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Cary O. Harding
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA
4 shared publications - Jerry Vockley
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, USA
4 shared publications - Barbara K. Burton
Northwestern University Feinberg School of Medicine, Chicago, USA
3 shared publications - Kevin Larimore
BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, USA
3 shared publications - Melissa Lah
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA
3 shared publications - Nicola Longo
Division of Clinical Genetics, Department of Human Genetics, University of California Los Angeles, Los Angeles, CA
3 shared publications
Latest Publications
- Open Access
- 8 February 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 147 (4) , 109768
Management of pegvaliase-related skin concerns: best practice recommendations using a modified Delphi approach
- 8 February 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 147 (4) , 109768
Open AccessManagement of pegvaliase-related skin concerns: best practice recommendations using a modified Delphi approach
- 15 June 2022
- Published by Springer Nature
- p. 257-275
Organic Acidemias
- 15 June 2022
- Published by Springer Nature
- p. 197-210
Homocystinuria and Cobalamin Disorders
- Open Access
- 14 August 2021
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 28, 100790
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- 14 August 2021
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 28, 100790
Open AccessUse of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- Open Access
- 1 August 2020
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 130 (4) , 239-246
Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up
- 1 August 2020
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 130 (4) , 239-246
Open AccessPegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up
- Open Access
- 4 July 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-11
Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Mean (standard deviation [SD]) plasma Phe at treatment-naïve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39)% from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5% of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8%); the most common AEs were injection-site reaction (72.5%), injection-site erythema (67.5%), headache (67.5%), and arthralgia (65.0%). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. ClinicalTrials.gov , NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703
- 4 July 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 1-11
Open AccessLong-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU. This study aimed to characterize the long-term efficacy, safety, and immunogenicity of pegvaliase in adults with PKU. PAL-003 is an ongoing, open-label, long-term extension study of the pegvaliase dose-finding parent phase 2 studies. Participants continued the dose of pegvaliase from one of three parent studies, with dose adjustments to achieve a plasma Phe concentration between 60 and 600 μmol/L. Mean (standard deviation [SD]) plasma Phe at treatment-naïve baseline for 80 participants in the parent studies was 1302.4 (351.5) μmol/L. In the 68 participants who entered the extension study, plasma Phe decreased 58.9 (39)% from baseline, to 541.6 (515.5) μmol/L at Week 48 of treatment. Plasma Phe concentrations ≤120 μmol/L, ≤360 μmol/L, and ≤ 600 μmol/L were achieved by 78.7, 80.0, and 82.5% of participants, respectively. Mean (SD) protein intake at baseline was 69.4 (40.4) g/day (similar to the recommended intake for the unaffected population) and remained stable throughout the study. All participants experienced adverse events (AEs), which were limited to mild or moderate severity in most (88.8%); the most common AEs were injection-site reaction (72.5%), injection-site erythema (67.5%), headache (67.5%), and arthralgia (65.0%). The AE rate decreased from 58.3 events per person-year in the parent studies to 18.6 events per person-year in the extension study. Pegvaliase treatment in adults with PKU produced meaningful and persistent reductions in mean plasma Phe concentration with a manageable safety profile for most subjects that continued with long-term treatment. ClinicalTrials.gov , NCT00924703. Registered June 18, 2009, https://clinicaltrials.gov/ct2/show/NCT00924703
- Open Access
- 1 May 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 124 (1) , 27-38
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
- 1 May 2018
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 124 (1) , 27-38
Open AccessPegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
- 1 January 2015
- Published by Springer Nature
- p. 149-158
Homocystinuria: Diagnosis and Management